Literature DB >> 19749389

Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration?

P P Koopmans1, R Ellis, B M Best, S Letendre.   

Abstract

The continuous replication of HIV-1 in the central nervous system, in particular the brain, and its potential long-term deleterious effect is the focus of this review. Cognitive deficits are observed in a significant percentage of HIV-1-infected patients. That may occur despite successful peripheral suppression of the HIV-1 replication. Compartmentalisation of HIV-1 in the brain, genetic mutation of HIV-1, age, HCV coinfection and poor intracerebral penetration, as well as possibly a direct toxic effect of antiretroviral drugs, are factors that may account for potential creeping damage of the brain after many years of treatment. Patients with neurological symptoms or cognitive deficits may require another approach to the treatment of their HIV infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19749389      PMCID: PMC5077299     

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  72 in total

Review 1.  Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy.

Authors:  David S Miller; Björn Bauer; Anika M S Hartz
Journal:  Pharmacol Rev       Date:  2008-06-17       Impact factor: 25.468

2.  Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.

Authors:  M C Strain; S Letendre; S K Pillai; T Russell; C C Ignacio; H F Günthard; B Good; D M Smith; S M Wolinsky; M Furtado; J Marquie-Beck; J Durelle; I Grant; D D Richman; T Marcotte; J A McCutchan; R J Ellis; J K Wong
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

3.  Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.

Authors:  Asa Mellgren; Andrea Antinori; Paola Cinque; Richard W Price; Christian Eggers; Lars Hagberg; Magnus Gisslén
Journal:  Antivir Ther       Date:  2005

Review 4.  HIV pharmacology: barriers to the eradication of HIV from the CNS.

Authors:  Bryan McGee; Nathalie Smith; Francesca Aweeka
Journal:  HIV Clin Trials       Date:  2006 May-Jun

5.  HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir.

Authors:  E R Lanier; G Sturge; D McClernon; S Brown; M Halman; N Sacktor; J McArthur; J H Atkinson; D Clifford; R W Price; D Simpson; G Torres; J Catalan; K Marder; C Power; C Hall; C Romero; B Brew
Journal:  AIDS       Date:  2001-04-13       Impact factor: 4.177

6.  Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.

Authors:  Valerio Tozzi; Pietro Balestra; Rita Bellagamba; Angela Corpolongo; Maria Flora Salvatori; Ubaldo Visco-Comandini; Chrysoula Vlassi; Marinella Giulianelli; Simonetta Galgani; Andrea Antinori; Pasquale Narciso
Journal:  J Acquir Immune Defic Syndr       Date:  2007-06-01       Impact factor: 3.731

7.  Early viral brain invasion in iatrogenic human immunodeficiency virus infection.

Authors:  L E Davis; B L Hjelle; V E Miller; D L Palmer; A L Llewellyn; T L Merlin; S A Young; R G Mills; W Wachsman; C A Wiley
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

8.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

9.  Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance.

Authors:  Arabella Bestetti; Silvia Presi; Chiara Pierotti; Simona Bossolasco; Serena Sala; Sara Racca; Paola Carrera; Adriano Lazzarin; Paola Cinque
Journal:  J Neurovirol       Date:  2004       Impact factor: 2.643

10.  Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.

Authors:  Serena S Spudich; Annelie C Nilsson; Nicole D Lollo; Teri J Liegler; Christos J Petropoulos; Steven G Deeks; Ellen E Paxinos; Richard W Price
Journal:  BMC Infect Dis       Date:  2005-11-02       Impact factor: 3.090

View more
  9 in total

1.  The role of neuroplasticity and cognitive reserve in aging with HIV: recommendations for cognitive protection and rehabilitation.

Authors:  David E Vance; Pariya L Fazeli; Joan S Grant; Larry Z Slater; James L Raper
Journal:  J Neurosci Nurs       Date:  2013-10       Impact factor: 1.230

2.  A peripheral monocyte interferon phenotype in HIV infection correlates with a decrease in magnetic resonance spectroscopy metabolite concentrations.

Authors:  Lynn Pulliam; Hans Rempel; Bing Sun; Linda Abadjian; Cyrus Calosing; Dieter J Meyerhoff
Journal:  AIDS       Date:  2011-09-10       Impact factor: 4.177

3.  Assessing and treating forgetfulness and cognitive problems in adults with HIV.

Authors:  David E Vance; Pariya L Fazeli; Linda Moneyham; Norman L Keltner; James L Raper
Journal:  J Assoc Nurses AIDS Care       Date:  2013 Jan-Feb       Impact factor: 1.354

4.  Peripheral biomarkers do not correlate with cognitive impairment in highly active antiretroviral therapy-treated subjects with human immunodeficiency virus type 1 infection.

Authors:  Bing Sun; Linda Abadjian; Hans Rempel; Cyrus Calosing; Johannes Rothlind; Lynn Pulliam
Journal:  J Neurovirol       Date:  2010-03       Impact factor: 2.643

Review 5.  Update on HIV dementia and HIV-associated neurocognitive disorders.

Authors:  Bruce J Brew; Phillip Chan
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

Review 6.  HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment.

Authors:  Phillip Chan; Bruce J Brew
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

7.  Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.

Authors:  Luis B Tovar-y-Romo; Namandjé N Bumpus; Daniel Pomerantz; Lindsay B Avery; Ned Sacktor; Justin C McArthur; Norman J Haughey
Journal:  J Pharmacol Exp Ther       Date:  2012-09-13       Impact factor: 4.030

8.  Prevention, Rehabilitation, and Mitigation Strategies of Cognitive Deficits in Aging with HIV: Implications for Practice and Research.

Authors:  David E Vance
Journal:  ISRN Nurs       Date:  2013-02-03

9.  Associations between brain microstructures, metabolites, and cognitive deficits during chronic HIV-1 infection of humanized mice.

Authors:  Michael D Boska; Prasanta K Dash; Jaclyn Knibbe; Adrian A Epstein; Sidra P Akhter; Natasha Fields; Robin High; Edward Makarov; Stephen Bonasera; Harris A Gelbard; Larisa Y Poluektova; Howard E Gendelman; Santhi Gorantla
Journal:  Mol Neurodegener       Date:  2014-12-18       Impact factor: 14.195

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.